Citations 0
April 2008

How to Predict the Risk of Parkinson Disease in Relatives of Parkin Mutation CarriersA Complex Puzzle of Age, Penetrance, and Number of Mutated Alleles

Author Affiliations

Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008

Arch Neurol. 2008;65(4):443-444. doi:10.1001/archneur.65.4.443

Doubt is not a pleasant condition, but certainty is absurd. Voltaire (1694-1778)

Mutations in the recessively inherited Parkin gene (OMIM 600116) are the most common known cause of early-onset Parkinson disease (PD) and account for as many as 77% of the patients with a juvenile or very young age of onset (< 30 years)1 and about 10% of a population-based sample with early-onset PD beginning at younger than 50 years.2 Although homozygous or compound-heterozygous Parkin mutations (ie, 2 mutated Parkin alleles) have only rarely been found in late-onset disease, the presence of a single heterozygous mutation has been suggested as a susceptibility factor for the development of later-onset PD based on family, case-control, and neuroimaging studies.3 A similar role has been discussed for mutations in the other recessive PD genes (ie, PINK1 [OMIM 605909 ], DJ-1 [OMIM 606324], and, recently, ATP13A2 [OMIM 606693]).4 Although 2 mutated alleles are a relatively rare finding even in the case of the Parkin gene, single heterozygous mutations are much less uncommon and are estimated to occur at a frequency of about 0.6% to 3.0% in the healthy population.5,6 If, indeed, single Parkin mutations represented a risk factor for PD, a higher prevalence of PD among carriers of heterozygous mutations would be expected than in individuals without such alterations. To our knowledge, only 4 studies systematically examine the role of different numbers of mutated Parkin alleles using a case-control design. Two of these studies6,7 reported equal numbers of mutations among patients and control subjects, whereas the other 2 investigations5,8 found an excess of mutations among patients.

First Page Preview View Large
First page PDF preview
First page PDF preview